S&P 500   3,006.06 (+0.55%)
DOW   27,081.66 (+0.30%)
QQQ   194.23 (+0.62%)
AAPL   235.90 (+0.65%)
FB   189.99 (+0.23%)
MSFT   140.78 (+0.26%)
GOOGL   1,257.91 (+1.20%)
AMZN   1,790.74 (+0.75%)
CGC   20.30 (+2.89%)
NVDA   195.65 (+0.74%)
MU   45.95 (+1.75%)
BABA   176.83 (-0.16%)
TSLA   261.37 (+0.62%)
AMD   31.29 (+1.56%)
F   9.09 (+0.22%)
NFLX   297.18 (+3.81%)
DIS   131.66 (+0.61%)
S&P 500   3,006.06 (+0.55%)
DOW   27,081.66 (+0.30%)
QQQ   194.23 (+0.62%)
AAPL   235.90 (+0.65%)
FB   189.99 (+0.23%)
MSFT   140.78 (+0.26%)
GOOGL   1,257.91 (+1.20%)
AMZN   1,790.74 (+0.75%)
CGC   20.30 (+2.89%)
NVDA   195.65 (+0.74%)
MU   45.95 (+1.75%)
BABA   176.83 (-0.16%)
TSLA   261.37 (+0.62%)
AMD   31.29 (+1.56%)
F   9.09 (+0.22%)
NFLX   297.18 (+3.81%)
DIS   131.66 (+0.61%)
Log in

Cue Biopharma Stock Price, News & Analysis (NASDAQ:CUE)

+0.03 (+0.41 %)
(As of 10/17/2019 10:12 AM ET)
Today's Range
Now: $7.27
50-Day Range
MA: $8.19
52-Week Range
Now: $7.27
Volume1,305 shs
Average Volume87,600 shs
Market Capitalization$164.16 million
P/E RatioN/A
Dividend YieldN/A
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CUE



Sales & Book Value

Annual Sales$1.14 million
Book Value$1.64 per share


Net Income$-38,980,000.00
Net Margins-2,039.41%


Market Cap$164.16 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) posted its earnings results on Thursday, August, 8th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.10. The business had revenue of $1.06 million for the quarter. Cue Biopharma had a negative net margin of 2,039.41% and a negative return on equity of 151.93%. View Cue Biopharma's Earnings History.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Cue Biopharma.

What price target have analysts set for CUE?

1 Wall Street analysts have issued 1-year target prices for Cue Biopharma's stock. Their forecasts range from $13.00 to $13.00. On average, they expect Cue Biopharma's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price. View Analyst Price Targets for Cue Biopharma.

What is the consensus analysts' recommendation for Cue Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

News stories about CUE stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cue Biopharma earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Cue Biopharma.

Are investors shorting Cue Biopharma?

Cue Biopharma saw a drop in short interest in September. As of September 15th, there was short interest totalling 1,140,000 shares, a drop of 6.6% from the August 15th total of 1,220,000 shares. Based on an average daily trading volume, of 93,500 shares, the days-to-cover ratio is presently 12.2 days. Approximately 6.4% of the company's shares are short sold. View Cue Biopharma's Current Options Chain.

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the folowing people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $7.27.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $164.16 million and generates $1.14 million in revenue each year. The company earns $-38,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.View Additional Information About Cue Biopharma.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is http://www.cuebiopharma.com/.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]

MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Featured Article: Marijuana Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel